Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
  • ?
Routes of
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Elimination half-life35 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass398.341 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Melarsoprol


Most recent articles on Melarsoprol

Most cited articles on Melarsoprol

Review articles on Melarsoprol

Articles on Melarsoprol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Melarsoprol

Images of Melarsoprol

Photos of Melarsoprol

Podcasts & MP3s on Melarsoprol

Videos on Melarsoprol

Evidence Based Medicine

Cochrane Collaboration on Melarsoprol

Bandolier on Melarsoprol

TRIP on Melarsoprol

Clinical Trials

Ongoing Trials on Melarsoprol at Clinical

Trial results on Melarsoprol

Clinical Trials on Melarsoprol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Melarsoprol

NICE Guidance on Melarsoprol


FDA on Melarsoprol

CDC on Melarsoprol


Books on Melarsoprol


Melarsoprol in the news

Be alerted to news on Melarsoprol

News trends on Melarsoprol


Blogs on Melarsoprol


Definitions of Melarsoprol

Patient Resources / Community

Patient resources on Melarsoprol

Discussion groups on Melarsoprol

Patient Handouts on Melarsoprol

Directions to Hospitals Treating Melarsoprol

Risk calculators and risk factors for Melarsoprol

Healthcare Provider Resources

Symptoms of Melarsoprol

Causes & Risk Factors for Melarsoprol

Diagnostic studies for Melarsoprol

Treatment of Melarsoprol

Continuing Medical Education (CME)

CME Programs on Melarsoprol


Melarsoprol en Espanol

Melarsoprol en Francais


Melarsoprol in the Marketplace

Patents on Melarsoprol

Experimental / Informatics

List of terms related to Melarsoprol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Melarsoprol (INN) is a prodrug used in the treatment of East African (rhodesiense) human African trypanosomiasis.[1] It is produced by Sanofi-Aventis and is on the World Health Organization's List of Essential Medicines.[2]

Freidheim demonstrated in 1949 the effects of melarsoprol against late-state trypanosomiasis. Melarsoprol is the dimercaptopropanol derivative of melarsen oxide (Mel Ox), whose structure is shown below:[3]

The main drug prescribed is Mel B, however, an alarming number of side effects occur from treatment. The active metabolite of Mel B is Mel Ox, which is taken up by the TbAT1 adenosine transporter in T. brucei brucei.[4] Due to side effects similar to arsenic poisoning, other pharmacological agents have become first-line treatments for stage one of the disease and for certain trypanosomes.


All people with confirmed trypanosome-caused disease must be treated. Treatment differs based on whether disease levels are considered stage 1 or stage 2 and based on which specific trypanosome has infected a patient. Below are treatment options (all adapted from [5]).

Melasarprol is used in the treatment of the second stage of the disease, and is the only treatment available for late-stage T. b. rhodesiense treatment.[6]

Mechanism of action

Melarsoprol is a prodrug, which is metabolized to melarsen oxide (Mel Ox) as its active form. Mel Ox is an arsen-oxide which irreversibly binds to vicinal sulfhydryl groups causing the inactivation of enzymes. The inability to distinguish between host and parasites renders this drug highly toxic with many side effects.

Mel Ox reacts with trypanothione (a spermidine-glutathione adduct which replaces glutathione in trypanosomes). Binding to this adduct forms a melarsen oxide-trypanothione adduct (Mel T) which competitively inhibits trypanothione reductase, effectively killing the parasitic cell.[3]


Two arsenic-containing stereoisomers exist in a 3:1 molar ratio. As melarsarprol is insoluble in water, dosage occurs via a 3.6% propylene glycol intravenous injection.[3]


The half-life of melarsoprol is less than 1 hour, but bioassays indicate a 35-hour half-life. This is indicative of pharmacologic agents with active metabolites. One such metabolite, Mel Ox, reaches maximum plasma levels about 15 minutes after melarsoprol injection. Clearance is at 21.5 ml/min/kg and Mel Ox half-life is 3.9 hours.[7]

Failure Rates & Resistance

Failure rates of 20-27% in certain African countries have been reported. These are linked to both drug resistance and other mechanisms which have not yet been elucidated. Resistance is likely due to transport problems associated with the P2 transporter, an adenine-adenosine transporter. Resistance can occur with point mutations within this transporter.[3]

Therapeutic uses

Due to high toxicity, melarsarprol is reserved only for the most dangerous of cases - stage 2 infection. Other agents with lower toxicity are used in stage 1.[1] The 2009 approval of nifurtimoxeflornithine combination therapy (NECT) for the treatment of T. b. gambiense served to limit merlarsoprol to the treatment of second-stage T. b. rhodesiense solely.[8]

Side effects

Being a toxic organic compound of arsenic, melarsoprol is a highly dangerous treatment which is only administered by injection under the supervision of a physician, as it can produce similar effects as arsenic poisoning. Among clinicians, it is colloquially referred to as "arsenic in antifreeze".[9] It is known to cause a range of side effects including convulsions, fever, loss of consciousness, rashes, bloody stools, nausea, and vomiting. It causes encephalopathy in 5–10% of cases, of which 40% die.[10]


  1. 1.0 1.1 Bisser S; N'Siesi FX; Lejon V; et al. (2007). "Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei rhodesiense sleeping sickness". J. Infect. Dis. 195 (3): 322–9. doi:10.1086/510534. PMID 17205469. Unknown parameter |author-separator= ignored (help)
  2. "WHO Model List of Essential Medicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
  3. 3.0 3.1 3.2 3.3 Brunton L (2011). "Goodman & Gillman's The Pharmacological Basis of Therapeutics". McGraw Hill Medical: 1427–28.
  4. Schweingruber ME (2004). "The Melaminophenyl Arsenicals Melarsoprol and Melarsen Oxide Interfere with Thiamine Metabolism in the Fission Yeast Schizosaccharomyces pombe". Antimicrobial Agents and Chemotherapy. 48 (9): 3268–3271. doi:10.1128/AAC.
  5. CDC (2013). "Disease Control and Prevention: Parasites Africian Trypanosomiasis".
  6. World Health Organization (2013). "Human African Trypanosomiasis" Check |url= value (help).
  7. Keiser J.; Ericsson O; Burri C (2000). "Investigations of the metabolites of the trypanocidal drug melarsoprol". Clinical Pharmacology. 67: 478–88. Unknown parameter |author-separator= ignored (help)
  8. Farrar J (2014). "Manson's Tropical Diseases: Expert Consult-Online". 23: 616.
  9. Hollingham R (2005). "Curing diseases modern medicine has left behind". New Scientist. 2005 (2482): 40–41.
  10. Balasegaram M; Harris S; Checchi F; et al. (2006). "Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo". Bulletin of the WHO. 84 (10): 783–91. Unknown parameter |author-separator= ignored (help)